

**DIVISION OF OTC DRUG PRODUCTS  
CENTER FOR DRUG EVALUATION AND RESEARCH**

**ANNOUNCEMENT OF OTC DRUG FEEDBACK MEETING**

**BETWEEN:** Representatives of FDA

and

**Pfizer Consumer Healthcare**

**Michael Barnett, D.D.S., Consultant**

**Thierry Bilbault, Ph.D., Director, Product Development**

**D. Scott Harper, Ph.D., Section Director, Oral Care Technology  
Development**

**Robert Kohler, Regulatory Consultant**

**Lori Kumar, Ph.D., Senior Director, Clinical U Product Development-  
Oral Care R&D**

**Michael Lynch, D.M.D., Ph.D., Director, Clinical Research-Oral Care**

**Dawn M. Parkin, Manager, Regulatory Affairs**

**Mei-Miau Wu, Ph.D., Manager, Statistics**

**TOPIC:** Discuss clinical design of a proposed 6-month gingivitis study of  
Listerine with Fluoride

**DATE:** August 27, 2002

**TIME:** 12:00 p.m.

**LOCATION:** 9201 Corporate Boulevard  
Rockville, Maryland  
Conference Room S-400

Pursuant to the agency's policy statement published in the **FEDERAL REGISTER** of September 29, 1981 (46 FR 47740) and clarified April 1, 1983 (48 FR 14050) and February 4, 1985 (50 FR 4916), which includes provisions for agency meetings with industry or other interested persons, this feedback meeting is being announced.

All feedback meetings are open to the public and no prior reservation is necessary. For further information or to reconfirm that the meeting has not been rescheduled or canceled, call Elaine Abraham, 301-827-2222.

**ATTENTION: JENNIE BUTLER**

cc: Docket No. 80N-0295

**DATE FORWARDED:** \_\_\_\_\_

02 AUG 16 11 51 AM '02

80N-0295

MM/28